Please assess the completion status of the following clinical trial:

Trial Title: Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven inoperable locally advanced or metastatic adenocarcinoma of the stomach (including adenocarcinoma of the gastrooesophageal junction)~* Patient's age between 20 and 70 years old~* Measurable disease defined by RECIST criteria~* Patients with non-measurable disease could be enrolled in the phase I part of the study~* ECOG performance status ≤ 1~* Hgb ≥ 8g/dL, WBC ≥ 3 x 109/L , neutrophils count ≥ 1.5 x 109/L , platelets ≥100 x 109/L, Creatinine clearance ≥50 mL/min, Total bilirubin ≤ 1.5 X UNL, AST, ALT and ALP ≤ 2.5 x UNL~* No prior chemotherapy or more than 6 months from adjuvant chemotherapy or chemo-radiation~* Estimated life expectancy more than 3 months~* Written informed consent~Exclusion Criteria:~* Gastrointestinal bleeding~* Clinically relevant, symptomatic excessive amounts of ascites resulting in patient's discomfort~* CNS metastases~* History of hypersensitivity to fluoropyrimidines, docetaxel or platinum compounds~* Any previous chemotherapy or radiotherapy for advanced disease~* Patient pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment~* Patient (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment~* Known hypersensitivity reaction to the component of the treatment~* Active infection or malnutrition or bowel obstruction~* Legal incapacity or limited legal capacity~* Definite contraindications for the use of corticosteroids~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan~* Chronic inflammation of the bowel~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment~* Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent~* A second primary tumor other than non-melanoma skin cancer or in situ cervical cancer

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Panitumumab plus DCF

Based on this trial design, predict the completion outcome and termination type (if applicable).